Secretariat Lead of the G20’s Global AMR R&D Hub: Could this be you?

Dear All:

As you may know, the G20 are establishing an AMR R&D Hub that will encourage and promote coordinated global action on AMR. The hub will be based in the Berlin office of the German Center for Infection Research (DZIF) and Germany will finance it for the first three years. There is now a public call to recruit the leader of this hub. Here is the key text from the the online job description (emphasis is mine):

In their Declaration from July 7 and 8, 2017 the G20 Leaders “call for a new international R&D Collaboration Hub to maximize the impact of existing and new antimicrobial basic and clinical research initiatives as well as product development”. This Global AMR R&D Hub shall promote high-level coordination and alignment of the existing public and private funding and leverage further investments for AMR R&D initiatives on a national and/or international level. The Global AMR R&D Hub shall become a central platform to provide guidance for governments and non-governmental funders on R&D funding priorities in the field. The scope of the Global AMR R&D Hub is embedded in a comprehensive One Health Approach, comprising human and animal health as well as environmental aspects. Initially, the activities of the Global AMR R&D Hub shall focus on enabling the development of urgently needed products for the prevention, treatment and diagnosis of bacterial infections in humans.

For the implementation of the Global AMR R&D Hub a secretariat with up to five employees (including the position announced below) will be established within the German Center for Infection Research (DZIF) in Berlin, Germany. We are currently searching for one Secretariat Lead (Senior Level).

Could this be you or somebody you know? Please be sure to share this interesting and important job opportunity! All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1

Impact of PASTEUR: 9.9m lives saved, ROI of 125:1 Dear All (and with thanks to Kevin Outterson for being lead author on this newsletter), (wonkish alert on this one … refresh your coffee and dig in!) The Center for Global Development have released a blog post and a paper estimating the potential impact of the PASTEUR Act.

Five FDA RFPs! Antifungal animal models, MIC breakpoints, and more!

Dear All, I just today learned that FDA have posted their FY 2023 funding opportunities. All the details are on this webpage and I’m just going to reproduce the text below my signature for your reference. I’ll also add a few details in italics. Lots of good opportunities here! –jr John H. Rex, MD |

WAAW! Must-Read Article, A Quiz, A Video, A Call to Action

Notes: Newsflash … BARDA have opened their long-running BAA-18-100-SOL-00003 to include support for antifungal agents. Search for “antifungal” in the posted .pdf to find the text. The first deadline for proposals is 15 Dec 2022 and further deadlines will doubtless follow: as shown on page 9, this BAA has offered 4 deadlines/year since 2018!  Dear All, In

Fireside Chat with AMR Action Fund CIO Martin Heidecker

Dear All, Ahead of World Antimicrobial Awareness Week, I sat down with AMR Action Fund Chief Investment Officer Martin Heidecker for a Fireside Chat. It was a fabulous conversation that covered everything from how the Fund’s investment process works to what it’s looking for in portfolio companies to broader investment trends in the AMR space.  As

Scroll to Top